XCancer

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

Description:

Up to 30 evaluable participants with known or suspected breast cancer (BIRADS 5 by imaging) will undergo FTT PET/CT imaging before primary surgery or neoadjuvant therapy. Patients undergoing neoadjuvant therapy may choose to have a second FTT PET/CT scan after the start of therapy (1 days to 3 weeks). FTT PET/CT uptake will be correlated with pathology measures and treatment response, in subjects undergoing neoadjuvant therapy

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Phase:

Phase 1

Contacts:

Elizabeth McDonald, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT03083288 - Click here to see study on

ClinicalTrials.gov

FluorThanatrace

Isotope(s):
Target(s):
  • PARP
Ligand Class: Small Molecules
Inclusion
  • At least one breast lesion one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast MRI). Only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study. Patients that have a prior diagnosis of primary breast cancer in the opposite breast can be included.
  • Known or suspected (BIRADS 5 on imaging) primary breast cancer
  • Willing to allow use orcollection of pathology tissue for the purposes of research from either clinical biopsy or surgical procedure (if adequate tissue is available) or research only biopsy
Exclusion

Exclusion Criteria Not Yet Provided